SCHEMBL3388796

SCHEMBL3388796

CN(C)CC=C=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9879865 0.73
SCHEMBL8634645 0.71
SCHEMBL5558515 0.71
SCHEMBL30716226 0.69
Carbon Dioxide SCHEMBL28132271 0.67
SCHEMBL2436975 0.65
SCHEMBL2436973 0.65
Hydrochloric Acid SCHEMBL10418372 0.63
SCHEMBL29118924 0.63
SCHEMBL7053456 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11161837-B2 Benzofuran derivatives for the treatment of hepatitis C BRISTOL-MYERS SQUIBB COMPANY (US) 2021-11-02 US disclosed
US-20200291002-A1 BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C BRISTOL MYERS SQUIBB CO (US) 2020-09-17 US disclosed
CN-106866460-B A kind of Schiff bases Multifunction fluorescent probe and preparation method and application 东南大学 2018-05-15 CN disclosed
WO-2017165233-A1 BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2017-09-28 WO disclosed
CN-106866460-A A kind of Schiff bases Multifunction fluorescent probe and preparation method and application 东南大学 2017-06-20 CN disclosed
CN-106674219-A Preparation method of Riociguat intermediate 上海医药工业研究院 2017-05-17 CN disclosed
CN-101300012-B Use of Diaminopyrimidine as P2X3 and P2x2/3 modulators in preparing medicine for treating respiratory diseases HOFFMANN LA ROCHE 2011-09-14 CN disclosed
EP-1521749-B8 PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES NOVARTIS AG (CH) 2010-12-22 EP disclosed
US-20100160324-A1 PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES ASTEX THERAPEUTICS LIMITED (GB) 2010-06-24 US disclosed
CN-101300012-A Diaminopyrimidine as P2X3 and P2x2/3 modulators ROCHE PALO ALTO LLC (CH) 2008-11-05 CN disclosed
EP-1399440-A1 5-(2-AMINOPYRIMIDIN-4-YL)BENZISOXAZOLES AS PROTEIN KINASE INHIBITORS Vertex Pharmaceuticals Incorporated (US) 2004-03-24 EP disclosed
WO-2004005282-A1 PHENYL-[4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES NOVARTIS AG (CH) 2004-01-15 WO disclosed
US-20040005637-A1 Intermediate products, methods for their preparation and use thereof BIOTAGE AB (SE) 2004-01-08 US disclosed
WO-2003101933-A1 INTERMEDIATE PRODUCTS, METHODS FOR THEIR PREPARATION AND USE THEREOF PERSONAL CHEMISTRY I UPPSALA AB (SE) 2003-12-11 WO disclosed
EP-1367045-A1 Intermediate products, methods for their preparation and use thereof Personal Chemistry i Uppsala AB (SE) 2003-12-03 EP disclosed
US-20030191156-A1 Beta3 adrenergic agonists JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT 2003-10-09 US disclosed
EP-1303509-A1 BETA3 ADRENERGIC AGONISTS ELI LILLY AND COMPANY (US) 2003-04-23 EP disclosed
WO-2002102800-A1 5-(2-AMINOPYRIMIDIN-4-YL) BENZISOXAZOLES AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2002-12-27 WO disclosed
WO-2002006276-A1 BETA3 ADRENERGIC AGONISTS ELI LILLY AND COMPANY (US) 2002-01-24 WO disclosed
WO-1994029300-A1 PYRAZOLE FUNGICIDES 3-SUBSTITUTED BY A HETEROCYCLIC RING RHONE POULENC AGROCHIMIE (FR) 1994-12-22 WO disclosed